0001171843-25-005890.txt : 20250912 0001171843-25-005890.hdr.sgml : 20250912 20250912170121 ACCESSION NUMBER: 0001171843-25-005890 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250909 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250912 DATE AS OF CHANGE: 20250912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Predictive Oncology Inc. CENTRAL INDEX KEY: 0001446159 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 331007393 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36790 FILM NUMBER: 251312254 BUSINESS ADDRESS: STREET 1: 91 43RD STREET STREET 2: SUITE 110 CITY: PITTSBURGH STATE: PA ZIP: 15201 BUSINESS PHONE: 412-432-1500 MAIL ADDRESS: STREET 1: 91 43RD STREET STREET 2: SUITE 110 CITY: PITTSBURGH STATE: PA ZIP: 15201 FORMER COMPANY: FORMER CONFORMED NAME: Precision Therapeutics Inc. DATE OF NAME CHANGE: 20180314 FORMER COMPANY: FORMER CONFORMED NAME: Precision Therapeutic Inc. DATE OF NAME CHANGE: 20180208 FORMER COMPANY: FORMER CONFORMED NAME: Skyline Medical Inc. DATE OF NAME CHANGE: 20130807 8-K 1 f8k_090925.htm FORM 8-K
false 0001446159 0001446159 2025-09-09 2025-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): September 9, 2025

 

Predictive Oncology Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36790 33-1007393

(State or other jurisdiction of

incorporation or organization)

 (Commission File Number) (I.R.S. Employer Identification No.)

 

91 43rd Street, Suite 110

Pittsburgh, Pennsylvania 15201

(412) 432-1500

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

 

Trading Symbol(s)

 

 

Name of each exchange on which registered

Common stock, par value $0.01 per share POAI NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 9, 2025, the Board of Directors (the “Board”) of Predictive Oncology Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board, determined that it was appropriate to award restricted stock units (“RSUs”) as a form of compensation for employees, consultants and directors, to be granted under the Company’s 2024 Equity Incentive Plan. In connection therewith, the Board approved a form of Restricted Stock Unit Award Agreement.

 

Consistent with the above determination, on September 9, 2025, upon the recommendation of the Compensation Committee, the Board approved the grant of 124,959 RSUs to Raymond F. Vennare, the Company’s Chief Executive Officer and 97,000 RSUs to Josh Blacher, the Company’s Interim Chief Financial Officer. Each RSU represents the right to receive one share of the Company’s common stock upon vesting. The RSUs will vest in full on October 31, 2025, subject to continued service through the vesting date.

 

The form of Restricted Stock Unit Award Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K. The foregoing description of the RSU grants to Messrs. Vennare and Blacher is qualified in its entirety by reference to the complete terms and conditions of the form of Restricted Stock Unit Award Agreement, incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description of Exhibit
     
10.1   Form of Restricted Stock Unit Award Agreement
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  PREDICTIVE ONCOLOGY INC.
     
Date: September 12, 2025 By: /s/ Josh Blacher  
    Name: Josh Blacher
    Title: Interim Chief Financial Officer

 

 

 

 

 

 

 EX-10.1 2 exh_101.htm EXHIBIT 10.1

Exhibit 10.1

 

PREDICTIVE ONCOLOGY INC.

2024 EQUITY INCENTIVE PLAN

RESTRICTED STOCK UNIT AWARD AGREEMENT

 

 

Name of Grantee: [●]

No. of Restricted Stock Units: [●]

Grant Date: [●]

 

Pursuant to the Predictive Oncology Inc. 2024 Equity Incentive Plan, as amended from time to time (the “Plan”), Predictive Oncology Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (this “Award”) to the Grantee on the Grant Date, subject to the terms and conditions set forth in this Restricted Stock Unit Award Agreement (this “Agreement”). Each Restricted Stock Unit shall relate to one share of Common Stock of the Company (the “Stock”). Capitalized terms used but not otherwise defined in this Agreement have the meanings set forth in the Plan.

 

Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (a) the Restricted Stock Units have vested as provided in Section 2 of this Agreement, and (b) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.

 

Vesting of Restricted Stock Units. The restrictions and conditions of Section 1 of this Agreement shall lapse on [____________] (the “Vesting Date”), subject to the Grantee’s continued employment with or provision of services to the Company through the Vesting Date. Notwithstanding any other provision contained in this Agreement, if the Grantee’s employment with or provision of services to the Company is terminated by the Company without Cause, or to the extent the Grantee is a member of the Board of Directors the Grantee is required by the Company to resign from and terminate service on the Board of Directors for any reason other than Cause, in each case prior to the Vesting Date, the restrictions set forth in Section 1 of this Agreement shall lapse immediately upon such termination of employment or service. For this purpose, “Cause” shall have the meaning set forth in any employment, service or similar agreement between Grantee and the Company or any of its subsidiaries, or to the extent not set forth therein, shall mean any of the following: (i) the Grantee engages in willful misconduct or fails to follow the reasonable and lawful instructions of the board of directors, if such conduct is not cured within thirty (30) calendar days after the Company sends notice to the Grantee of the alleged Cause; (ii) the Grantee embezzles or misappropriates assets of the Company or any of its subsidiaries; (iii) the Grantee’s violation of the Grantee’s obligations pursuant to any employment or service agreement with the Company or any of its subsidiaries, if such conduct is not cured within thirty (30) calendar days after the Company sends written notice to the Grantee of the alleged Cause; (iv) the Grantee’s breach of any agreement between the Grantee and the Company or to which the Company and the Grantee are parties, or a breach by the Grantee of a fiduciary duty or responsibility to the Company; (v) the commission by the Grantee of fraud or other willful conduct that adversely affects the business or reputation of the Company, as determined in the Company’s sole discretion; or (vi) the Company has a reasonable belief the Grantee engaged in some form of harassment or other improper conduct prohibited by the Company policy or the law.

 

Termination of Relationship with the Company. If the Grantee ceases to be employed by or providing services to the Company prior to the Vesting Date set forth in Section 2 above, all unvested Restricted Stock Units shall automatically and without notice terminate and be forfeited without payment of any consideration therefor, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.

 

Issuance of Shares of Stock. No later than thirty (30) days following the date the Restricted Stock Units become vested in accordance with Section 2 above, the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Section 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such Stock.

 

Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Board of Directors or a Committee thereof as set forth in Section 2 of the Plan.

 

Tax Withholding. As a condition to this Award, the Grantee hereby agrees that any required federal, state, local, or foreign tax withholding obligations arising in connection with the vesting and settlement of this Award shall be satisfied, at the Grantee’s election, by either (a) authorizing the Company to withhold from the Stock otherwise deliverable upon settlement of the Award a number of shares of Stock having a Fair Market Value equal to the required tax withholding amount; or (b) remitting to the Company, by personal check, the full amount of the required tax withholding prior to the delivery of the Stock. If the Grantee fails to timely elect a method of tax withholding, the Company shall default to withholding shares of Stock in accordance with clause (a) of the foregoing sentence, unless prohibited by applicable law or unless the Company determines, in its sole discretion, that cash payment is required. For the avoidance of doubt, the Company shall not facilitate broker-assisted sales for the purpose of tax withholding. Unless the withholding tax obligations of the Company and/or any subsidiary thereof are satisfied by the Grantee in accordance with this provision, the Company shall have no obligation to issue any shares of Stock on the Grantee’s behalf pursuant to the vesting of this Award.

 

Section 409A of the Code. It is the intent that the terms relating to the vesting and payment of the Award as set forth in this Agreement shall qualify for exemption from or comply with the requirements of Section 409A of the Code, and any ambiguities herein will be interpreted to so qualify or comply. Notwithstanding the foregoing or anything herein to the contrary, if it is determined that this Award fails to satisfy the requirements of the “short-term deferral” exemption and is otherwise deferred compensation subject to Section 409A of the Code, and if the Grantee is considered a “specified employee” (as defined under Section 409A(a)(2)(B)(i) of the Code) as of the date of the Grantee’s “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h)), then the issuance of any shares of Stock that would otherwise be made upon the date of the separation from service or within the first six (6) months thereafter will not be made on the originally scheduled date and will instead be issued in a lump sum on the date that is six (6) months and one day after the date of the separation from service, but only if such delay in the issuance of the shares is necessary to avoid the imposition of additional taxation on the Grantee in respect of the Stock under Section 409A of the Code. The Company reserves the right, to the extent the Company deems necessary or advisable in its sole discretion, to unilaterally amend or modify this Agreement as may be necessary to ensure that all payments provided for under this Agreement are made in a manner that qualifies for exemption from or complies with Section 409A of the Code; provided, however, that the Company makes no representation that the vesting or payments pursuant to this Award provided for under this Agreement will be exempt from or comply with Section 409A of the Code and makes no undertaking to preclude Section 409A of the Code from applying to the vesting or payments pursuant to this Award or require that any vesting or payments pursuant to this Award comply with the require Section of 409A of the Code. The Company will have no liability to the Grantee or any other party if the Award, the delivery of shares of Stock upon payment of the Award or other payment hereunder that is intended to be exempt from, or compliant with, Code Section 409A, is not so exempt or compliant or for any action taken by the Company with respect thereto.

 

 

 

 

No Right to Continued Employment. Nothing contained in this Agreement shall be deemed to provide the Grantee any right to continue employment with or to continue providing services to the Company for any period of time and shall not limit the right of the Company, in its sole and absolute discretion, to terminate the Grantee’s employment or service at any time.

 

Amendment. Unless otherwise provided in the Plan or this Agreement, no provisions of this Agreement may be amended, modified, waived or discharged except by a written document signed by the Grantee and a duly authorized officer of the Company and approved by the Board of Directors. The failure of the Company to insist upon strict adherence to any term of this Agreement on any occasion will not be considered a waiver of such party’s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement.

 

Integration. This Agreement and the Plan shall constitute the entire understanding and agreement of the Grantee and the Company with respect to the subject matter contained herein or therein and supersede any prior agreements, understandings, restrictions, representations, or warranties between the Grantee and the Company with respect to such subject matter other than those as set forth or provided for herein or therein. To the extent contemplated herein or therein, the provisions of this Agreement shall survive any settlement of the Award and shall remain in full force and effect.

 

Governing Law. This Agreement and any claim, controversy or dispute arising under or related to this Agreement or the relationship of the parties will be governed exclusively by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.

 

Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under present or future laws effective during the term of this Agreement, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part of this Agreement; and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance from this Agreement; provided that, if any such provision may be made enforceable by limitation thereof, then such provision shall be deemed to be so limited and shall be enforceable to the maximum extent permitted by applicable law. Furthermore, in lieu of (and to the extent of) each such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and be legal, valid and enforceable.

 

Counterparts. This Agreement may be executed in two or more counterparts (including by PDF), each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

 

Other. The Grantee represents that the Grantee has read and is familiar with the provisions of the Plan and this Agreement and hereby accepts the Award subject to all of their terms and conditions.

 

Confidentiality. The Grantee hereby agrees to keep the terms of this Agreement confidential, and will not, except as required by law, disclose such terms to any person other than the Grantee’s immediate family or legal or financial advisers (who also must keep the terms of this Agreement confidential).

 

Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

 

[Signature Page Follows]

 

 

 

 

 

 

 

 

 

 

  PREDICTIVE ONCOLOGY INC.
   
  By:    
  Name: [●]
  Title: [●]

 

 

 

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Grantee (including through an online acceptance process) is acceptable.

 

 

GRANTEE  
   
By:      
Name: [●]  
   

ADDRESS:  [●]

  

 

 

 

 

 

 

 

 

 

[Signature Page to Restricted Stock Unit Award Agreement]

 

 EX-101.LAB 3 poai-20250909_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 poai-20250909_pre.xml XBRL PRESENTATION FILE EX-101.SCH 5 poai-20250909.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.25.2
Cover
Sep. 09, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 09, 2025
Entity File Number 001-36790
Entity Registrant Name Predictive Oncology Inc.
Entity Central Index Key 0001446159
Entity Tax Identification Number 33-1007393
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 91 43rd Street
Entity Address, Address Line Two Suite 110
Entity Address, City or Town Pittsburgh
Entity Address, State or Province PA
Entity Address, Postal Zip Code 15201
City Area Code (412)
Local Phone Number 432-1500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.01 per share
Trading Symbol POAI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://predictive-oncology.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_090925.htm poai-20250909.xsd poai-20250909_lab.xml poai-20250909_pre.xml http://xbrl.sec.gov/dei/2025 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_090925.htm": { "nsprefix": "POAI", "nsuri": "http://predictive-oncology.com/20250909", "dts": { "inline": { "local": [ "f8k_090925.htm" ] }, "schema": { "local": [ "poai-20250909.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "labelLink": { "local": [ "poai-20250909_lab.xml" ] }, "presentationLink": { "local": [ "poai-20250909_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 23 }, "report": { "R1": { "role": "http://predictive-oncology.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2025-09-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_090925.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-09-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_090925.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodStartDate", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Extension", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12gTitle", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityReportingObligation", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001171843-25-005890-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-25-005890-xbrl.zip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end XML 15 f8k_090925_htm.xml IDEA: XBRL DOCUMENT 0001446159 2025-09-09 2025-09-09 iso4217:USD shares iso4217:USD shares false 0001446159 8-K 2025-09-09 Predictive Oncology Inc. DE 001-36790 33-1007393 91 43rd Street Suite 110 Pittsburgh PA 15201 (412) 432-1500 false false false false Common stock, par value $0.01 per share POAI NASDAQ false